Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3205 in advanced malignant tumors
NCT07482592Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3205 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum tolerated dose at 21 days and 5 more. Started Apr 2026; status: recruiting.
02
Drugs
TQB3205
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07482592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482592.